Eveliqure initiates clinical safety and immunogenicity trials of its vaccine candidate against Shigellosis and ETEC in endemic populations in Bangladesh

Eveliqure Biotechnologies has announced the initiation of a Phase 1b clinical trial with ShigETEC, its vaccine candidate against shigellosis and Enterotoxigenic E. coli (ETEC) diseases, in Bangladesh. 


Eveliqure is developing ShigETEC both as a vaccine for children living in developing countries and for travellers to endemic regions. The placebo controlled, dose-escalating, age-descending Phase 1b clinical study will focus on assessing the safety, tolerability and immunogenicity of ShigETEC at the icddr,b (International Centre for Diarrheal Disease Research, Bangladesh) Clinical Trials Unit in Mirpur, Dhaka Metropolitan area, Bangladesh. 

These activities are supported by the EU-funded SHIGETECVAX international consortium of several organizations - Eveliqure Biotechnologies, icddr,b, the European Vaccine Initiative, University of Gothenburg, and PATH.


Read more here